biocryst pharmaceuticals inc. - BCRX
BCRX
Close Chg Chg %
7.30 0.15 1.99%
Open Market
7.45
+0.15 (1.99%)
Volume: 976.18K
Last Updated:
Nov 21, 2024, 1:53 PM EDT
Company Overview: biocryst pharmaceuticals inc. - BCRX
BCRX Key Data
| Open $7.30 | Day Range 7.02 - 7.46 |
| 52 Week Range 4.03 - 8.88 | Market Cap $1.51B |
| Shares Outstanding 207.13M | Public Float 196.10M |
| Beta 1.89 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.61 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 2.42M |
BCRX Performance
| 1 Week | 3.84% | ||
| 1 Month | -8.18% | ||
| 3 Months | -9.88% | ||
| 1 Year | 32.25% | ||
| 5 Years | 224.44% |
BCRX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
11
Full Ratings ➔
About biocryst pharmaceuticals inc. - BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.
BCRX At a Glance
BioCryst Pharmaceuticals, Inc.
4505 Emperor Boulevard
Durham, North Carolina 27703-8457
| Phone | 1-919-859-1302 | Revenue | 331.41M | |
| Industry | Biotechnology | Net Income | -226,539,000.00 | |
| Sector | Health Technology | 2023 Sales Growth | 22.37% | |
| Fiscal Year-end | 12 / 2024 | Employees | 536 | |
| View SEC Filings |
BCRX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.474 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -15.768 |
| Enterprise Value to Sales | 4.856 |
| Total Debt to Enterprise Value | 0.527 |
BCRX Efficiency
| Revenue/Employee | 618,305.97 |
| Income Per Employee | -422,647.388 |
| Receivables Turnover | 5.819 |
| Total Asset Turnover | 0.621 |
BCRX Liquidity
| Current Ratio | 3.307 |
| Quick Ratio | 3.115 |
| Cash Ratio | 2.605 |
BCRX Profitability
| Gross Margin | 98.094 |
| Operating Margin | -31.293 |
| Pretax Margin | -68.262 |
| Net Margin | -68.356 |
| Return on Assets | -42.464 |
| Return on Equity | N/A |
| Return on Total Capital | -57.616 |
| Return on Invested Capital | -55.835 |
BCRX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 215.856 |
| Total Debt to Total Assets | 164.174 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 209.189 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Biocryst Pharmaceuticals Inc. - BCRX
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 17.81M | 157.17M | 270.83M | 331.41M | |
Sales Growth
| -63.53% | +782.38% | +72.31% | +22.37% | |
Cost of Goods Sold (COGS) incl D&A
| 1.68M | 8.04M | 8.03M | 6.32M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 748.00K | 777.00K | 1.44M | 1.66M | |
Depreciation
| 748.00K | 777.00K | 1.44M | 1.66M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| -59.13% | +379.77% | -0.12% | -21.35% | |
Gross Income
| 16.14M | 149.13M | 262.80M | 325.10M | |
Gross Income Growth
| -63.93% | +824.20% | +76.22% | +23.71% | |
Gross Profit Margin
| +90.59% | +94.88% | +97.03% | +98.09% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 185.87M | 326.85M | 411.23M | 428.81M | |
Research & Development
| 122.96M | 208.03M | 251.86M | 214.91M | |
Other SG&A
| 62.90M | 118.82M | 159.37M | 213.89M | |
SGA Growth
| +28.91% | +75.85% | +25.82% | +4.27% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| (229.00K) | (55.14M) | 1.98M | 29.02M | |
EBIT after Unusual Expense
| (169.50M) | (122.58M) | (150.42M) | (132.73M) | |
Non Operating Income/Expense
| 1.19M | 62.00K | 5.13M | 14.74M | |
Non-Operating Interest Income
| 526.00K | 61.00K | 5.13M | 15.78M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 14.50M | 59.29M | 99.09M | 108.24M | |
Interest Expense Growth
| +21.94% | +308.90% | +67.12% | +9.23% | |
Gross Interest Expense
| 14.50M | 59.29M | 99.09M | 108.24M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (182.81M) | (181.81M) | (244.38M) | (226.23M) | |
Pretax Income Growth
| -67.88% | +0.55% | -34.42% | +7.43% | |
Pretax Margin
| -1,026.35% | -115.68% | -90.24% | -68.26% | |
Income Tax
| - | 2.25M | 2.73M | 310.00K | |
Income Tax - Current - Domestic
| - | - | 2.43M | (45.00K) | - |
Income Tax - Current - Foreign
| - | - | 292.00K | 1.04M | - |
Income Tax - Deferred - Domestic
| - | - | 11.00K | (120.00K) | - |
Income Tax - Deferred - Foreign
| - | - | - | (562.00K) | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (182.81M) | (184.06M) | (247.12M) | (226.54M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (182.81M) | (184.06M) | (247.12M) | (226.54M) | |
Net Income Growth
| -67.88% | -0.68% | -34.26% | +8.33% | |
Net Margin Growth
| -1,026.35% | -117.11% | -91.24% | -68.36% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (182.81M) | (184.06M) | (247.12M) | (226.54M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (182.81M) | (184.06M) | (247.12M) | (226.54M) | |
EPS (Basic)
| -1.093 | -1.0276 | -1.3292 | -1.1787 | |
EPS (Basic) Growth
| -16.03% | +5.98% | -29.35% | +11.32% | |
Basic Shares Outstanding
| 167.27M | 179.12M | 185.91M | 192.20M | |
EPS (Diluted)
| -1.093 | -1.0276 | -1.3292 | -1.1787 | |
EPS (Diluted) Growth
| -16.03% | +5.98% | -29.35% | +11.32% | |
Diluted Shares Outstanding
| 167.27M | 179.12M | 185.91M | 192.20M | |
EBITDA
| (168.98M) | (176.94M) | (147.00M) | (102.05M) | |
EBITDA Growth
| -71.15% | -4.71% | +16.92% | +30.57% | |
EBITDA Margin
| -948.70% | -112.58% | -54.28% | -30.79% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 15.10 | |
| Number of Ratings | 11 | Current Quarters Estimate | -0.074 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | -0.375 | |
| Last Quarter’s Earnings | -0.07 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.18 | Next Fiscal Year Estimate | -0.082 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 10 | 2 | 11 | 11 |
| Mean Estimate | -0.07 | -0.11 | -0.37 | -0.08 |
| High Estimates | -0.01 | -0.10 | -0.30 | 0.11 |
| Low Estimate | -0.16 | -0.11 | -0.46 | -0.24 |
| Coefficient of Variance | -60.16 | -6.73 | -12.20 | -170.31 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 10 | 9 | 10 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Biocryst Pharmaceuticals Inc. - BCRX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Biocryst Pharmaceuticals Inc. - BCRX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jun 26, 2024 | Amy E. McKee Director | 27,831 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.32 per share | 175,891.92 |
| Jun 18, 2024 | A. Machelle Sanders Director | 27,742 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6 per share | 166,452.00 |
| Jun 4, 2024 | Vincent J. Milano Director | 67,867 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $6.46 per share | 438,420.82 |
| Jun 4, 2024 | Theresa Marie Heggie Director | 52,730 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $6.46 per share | 340,635.80 |
| May 30, 2024 | Stephen J. Aselage Director | 2,500 | Open market or private purchase of non-derivative security Non-derivative transaction at $6.4 per share | 16,000.00 |
| May 22, 2024 | Nancy J. Hutson Director | 86,818 | Open market or private purchase of non-derivative security Non-derivative transaction at $6.38 per share | 553,898.84 |
| May 15, 2024 | Jon P. Stonehouse President & CEO; Director | 1,127,770 | Open market or private purchase of non-derivative security Non-derivative transaction at $5.55 per share | 6,259,123.50 |
| May 15, 2024 | Helen M. Thackray Chief R&D Officer | 272,139 | Open market or private purchase of non-derivative security Non-derivative transaction at $5.86 per share | 1,594,734.54 |
| May 15, 2024 | Alane P. Barnes Chief Legal Officer | 300,762 | Open market or private purchase of non-derivative security Non-derivative transaction at $5.53 per share | 1,663,213.86 |
| May 15, 2024 | Steven K. Galson Director | 51,551 | Open market or private purchase of non-derivative security Non-derivative transaction at $5.49 per share | 283,014.99 |
| May 15, 2024 | Charles K. Gayer Chief Commercial Officer | 307,533 | Open market or private purchase of non-derivative security Non-derivative transaction at $5.47 per share | 1,682,205.51 |
| May 15, 2024 | Anthony J. Doyle Chief Financial Officer | 266,744 | Open market or private purchase of non-derivative security Non-derivative transaction at $5.57 per share | 1,485,764.08 |